Israeli cancer immunotherapy company Compugen is to provide its pipeline of cancer-fighting antibodies to MedImmune – AstraZeneca’s global biologics research and development arm. Compugen will initially receive $10 million and then up to $200 million for the first MedImmune product.
https://www.calcalistech.com/ctech/articles/0,7340,L-3735453,00.html